The State of the Biosimilars Industry

Pfenex Inc. CEO, Dr. Bert Liang, discusses the state of the biosimilars industry with Pharmaceutical Processing. There is momentum in the space as the U.S. Food and Drug Administration (FDA) has published a number of biosimilar guidances and two biosimilars have been approved. FDA said at a June event there are 60 biosimilar products in development and nine applications have been submitted for biosimilar approval. Naming, coding, and interchangeability are some of the key policy issues taking shape, and education is paramount to driving uptake, according to Dr. Liang.

Read full article